Nippon India Nifty Pharma ETF
Category: ETFs
Launch Date: 05-07-2021
AUM:
₹ 1,356.27 Cr
Expense Ratio
0.21%
Benchmark
NIFTY Pharma TRI
ISIN
INF204KC1089
Minimum Investment
1000.0
Minimum Topup
0.0
Minimum SIP Amount
100
Fund Manager
Jitendra Tolani
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Nippon India Nifty Pharma ETF | 12.7 | 23.89 | - |
| Nifty Pharma TRI | 13.97 | 24.12 | 12.21 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
24.8942
Last change
0.09 (0.3708%)
Fund Size (AUM)
₹ 1,356.27 Cr
Performance
11.76% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Fund Manager
Jitendra Tolani
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 22.53 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 9.73 |
| Dr. Reddys Laboratories Ltd | 9.49 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 8.67 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 6.58 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 5.15 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 5.04 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.57 |
| GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 4.27 |
| ALKEM LABORATORIES LIMITED EQ | 3.71 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 99.98 |
Peer Comparison
| Scheme Name | 5Y (%) |
|---|---|
| Nippon India Nifty Pharma ETF | 0.0 |